Illumina, Inc. (ticker: ILMN, exchange: NASDAQ Global Select Market (.O))
News Release -
Solexa to Participate in Cancer Genome Project Panel Discussion at 2005 BIO InvestorForum
HAYWARD, Calif. & CAMBRIDGE, UK--(BUSINESS WIRE)--Oct. 20,
2005--Solexa, Inc. (Nasdaq:SLXA) today announced that John West, chief
executive officer of Solexa, will participate in panel presentation at
the 2005 BIO InvestorForum today, Thursday, October 20, 2005 at 6:30
p.m. Eastern Time (3:30 p.m. Pacific Time). The presentation, entitled
"Cancer Genome Project, Part I: Implications for Sequencing
Technology," will discuss the Human Cancer Genome Project and its
implications for technology and therapeutic industry participants.
The goal of the Human Cancer Genome Project is to obtain a
comprehensive description of the genetic basis of cancer. The ultimate
aim of the National Institutes of Health (NIH) is to better understand
the initiation, progression, response to therapy and diagnosis of
cancer. This comprehensive knowledge of the genetic basis of cancer
would provide a permanent foundation for all future cancer research
and would have far-reaching implications for the creation of new
diagnostics and therapeutics. As contemplated, this ten-year, $1.5
billion effort would profile 50 tumor types, each in 250 individuals.
The National Cancer Institute (NCI) and National Human Genome Research
Institute (NHGRI), which supported the NIH component of the Human
Genome Project, have jointly committed a total of $100 million in a
pilot project to begin in 2006.
Interested investors may gain access to a live audio webcast of
the presentation via the Internet by visiting the "News-Conferences
and Exhibitions" section of the Company's Web site at www.solexa.com.
The presentation will be archived on the Web site and available for 14
days. Additional information about the 2005 BIO InvestorForum is
available at www.bio.org.
Solexa, Inc. is developing and preparing to commercialize a new
genetic analysis instrument system which will be used to perform a
range of analyses including whole genome resequencing, gene expression
analysis and micro-RNA analysis. Solexa expects its first-generation
technology to generate over a billion bases of DNA sequence per run
and to enable whole genome resequencing below $100,000 per sample,
making it the first platform to reach this important milestone.
Solexa's longer-term goal is to reduce the cost of human re-sequencing
to a few thousand dollars for use in a wide range of applications from
basic research through clinical diagnostics. The Company expects to
introduce its first instrument system by the end of 2005. For further
information, please visit www.solexa.com.
This press release contains "forward-looking" statements,
including statements related to the current views of Solexa management
as to future products, product development including the commercial
introduction of the Company's novel genetic analysis technology, the
expansion and success of Solexa's commercial application of its
genomics technologies and the future financial performance of Solexa.
Any statements contained in this press release that are not statements
of historical fact may be deemed to be forward-looking statements.
Words such as "believes," "anticipates," "plans," "predicts,"
"expects," "envisions," "hopes," "estimates," "intends," "will,"
"continue," "may," "potential," "should," "confident," "could" and
similar expressions are intended to identify forward-looking
statements. There can be no assurance that such expectations of any of
the forward-looking statements will prove to be correct, and actual
results could differ materially from those projected or assumed in the
forward-looking statements. There are a number of important factors
that could cause the results of Solexa to differ materially from those
indicated by these forward-looking statements including, among others,
risks detailed from time to time in the Company's SEC reports,
including its Annual Report on Form 10-K for the year ended December
31, 2004 and its Form 10-Q for the quarter ended June 30, 2005. Solexa
does not undertake any obligation to update forward-looking
CONTACT: Solexa, Inc.
Omead Ostadan, 510-670-9300
European Media Contact:
Sue Charles, +44 (0)20 7886 8152
Lippert/Heilshorn & Associates
Jody Cain (email@example.com)
Mariann Ohanesian (firstname.lastname@example.org)
U.S. Media Contact:
Mark Stuart (email@example.com)
SOURCE: Solexa, Inc.